TABLE 10.

Results of meta-analyses estimating summary prevalence of stone clearance by intraductal and conventional therapy for all studies and subgroups defined by attributes of studies and clinical features of patients

	Intraductal therapy		Conventional therapy
	No. of contributing studies	Summary estimates of proportion (95% confidence interval)	No. of contributing studies	Summary estimates of proportion (95% confidence interval)
Overall results
All studies	58	.92 (.90-.94)	124	.92 (.90-.94)
Subgroups of studies defined by single factors
Year study conducted
Before 2007	19	.89 (.85-.93)	17	.75 (.64-.84)
2007 and later	39	.93 (.91-.95)	107	.94 (.92-.95)
Use of papillary dilation
Without	52	.92 (.89-.94)	38	.81 (.75-.87)
With	6	.92(.87-.96)	86	.95 (.94-.96)
Geographic region
Western country*	37	.91 (.88-.94)	34	.84 (.78-.89)
Eastern country†	21	.94 (.91-.97)	90	.95 (.93-.96)
Study design
Prospective cohorts	8	.91 (.84-.96)	93	.91 (.88-.94)
Retrospective cohorts	50	.92 (.90-.94)	31	.92 (.90-.94)
Type of report
Full article	46	.92 (.89-.94)	88	.92 (.89-.94)
Abstract	12	.93 (.88-.96)	36	.93 (.89-.96)
Subgroups defined by use of papillary dilation, overall, and further stratified on year and geographic region of study
Without papillary dilation	52	.92 (.89-.94)	38	.81 (.75-.87)
Before 2007	19	.90 (.85-.93)	16	.74 (.63-.84)
2007 and later	33	.93 (.90-.96)	22	.86 (.80-.93)
Western country*	33	.91 (.88-.94)	15	.71 (.58-.83)
Eastern country†	19	.94 (.90-.97)	23	.86 (.75-.87)
With papillary dilation	6	.92 (.87-.96)	86	.95 (.94-.96)
Before 2007	0	—	1	.88 (.77-.94)
After 2007	6	.92 (.87-.96)	86	.95 (.94-.96)
Western country*	4	.91 (.83-.98)	20	.90 (.86-.94)
Eastern country†	2	.93 (.85-.99)	66	.96 (.95-.97)

—, Not applicable.

^*Europe, United States, Canada, Australia.

^†Asia, Latin America.